Literature DB >> 10396027

A sensitive and specific in vitro bioassay for activin using a mouse plasmacytoma cell line, MPC-11.

D J Phillips1, J N Brauman, A J Mason, D M de Kretser, M P Hedger.   

Abstract

A new in vitro bioassay for activin was developed using the mouse plasmacytoma cell line, MPC-11. Human recombinant (hr) activin A dose-dependently inhibited the proliferation of these cells, whereas a range of other factors, including inhibin, follistatin and transforming growth factor-beta1, -beta2 and -beta3 had no effect. Conditioned medium containing activin B induced an inhibition similar to hr-activin A. The inhibitory influence of activin A could be blocked by follistatin, but not by hr-inhibin A. This bioassay had a sensitivity for activin A of around 0.4 ng/ml, an ED50 response of 3.5 ng/ml, and an intra-assay coefficient of variation of <11%. It offers substantial advantages over existing in vitro activin bioassays in terms of ease of use, specificity and throughput. The utility of the MPC-11 bioassay was demonstrated in the purification of activin from amniotic fluid, where an almost identical profile of bioactive activin A was detected compared with the pituitary cell bioassay of activin. Bioactive activin could also be detected in unpurified ovine allantoic and amniotic fluids and bovine follicular fluid. Measuring activin in untreated and heat-treated human sera or seminal plasma was hampered by a non-specific inhibitory effect, so that several serum samples did not run parallel with the hr-activin A standard. This inhibitory effect by serum could not be overcome by addition of follistatin, suggesting it is not activin-like bioactivity. This new bioassay for activin demonstrates widespread applicability for monitoring of purified or partially purified samples during purification procedures, bioactivity measurements, receptor-binding studies and assays of cell culture medium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10396027     DOI: 10.1677/joe.0.1620111

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  5 in total

1.  Serum activin A and B levels predict outcome in patients with acute respiratory failure: a prospective cohort study.

Authors:  David Morritz de Kretser; Jonathan Guy Bensley; Ville Pettilä; Rita Linko; Mark Peter Hedger; Susan Hayward; Carolyn Anne Allan; Robert Ian McLachlan; Helen Ludlow; David James Phillips
Journal:  Crit Care       Date:  2013-10-31       Impact factor: 9.097

2.  An Easy and Fast Method for Production of Chinese Hamster Ovary Cell Line Expressing and Secreting Human Recombinant Activin A.

Authors:  Hassan Rassouli; Ali Sayadmanesh; Siamak Rezaeiani; Zahra Ghezelayagh; Mohammad Reza Gharaati; Yaser Tahamtani
Journal:  Cell J       Date:  2019-10-14       Impact factor: 2.479

3.  Combined administration of testosterone plus an ornithine decarboxylase inhibitor as a selective prostate-sparing anabolic therapy.

Authors:  Ravi Jasuja; James C Costello; Rajan Singh; Vandana Gupta; Catherine S Spina; Gianluca Toraldo; Hyeran Jang; Hu Li; Carlo Serra; Wen Guo; Pratibha Chauhan; Navjot S Narula; Tyler Guarneri; Ayla Ergun; Thomas G Travison; James J Collins; Shalender Bhasin
Journal:  Aging Cell       Date:  2013-12-04       Impact factor: 9.304

4.  Systemic administration of follistatin288 increases muscle mass and reduces fat accumulation in mice.

Authors:  Samudra S Gangopadhyay
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

5.  Role of Activins in Hepcidin Regulation during Malaria.

Authors:  Natasha Spottiswoode; Andrew E Armitage; Andrew R Williams; Alex J Fyfe; Sumi Biswas; Susanne H Hodgson; David Llewellyn; Prateek Choudhary; Simon J Draper; Patrick E Duffy; Hal Drakesmith
Journal:  Infect Immun       Date:  2017-11-17       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.